[Björk-Shiley-Monostrut prosthesis of the aortic valve. Mid-term development].

PubWeight™: 0.80‹?›

🔗 View Article (PMID 2012486)

Published in Arch Mal Coeur Vaiss on January 01, 1991

Authors

P Canivet1, B Vitoux, A Vahanian, P L Michel, B Cormier, L Enriquez Sarano, C Richaud, J Acar

Author Affiliations

1: Service de cardiologie, hôpital Tenon, Paris.

Articles citing this

Long-term experience with the Bjork-Shiley Monostrut tilting disc valve. J Korean Med Sci (2007) 0.75

Articles by these authors

Bartonella (Rochalimaea) quintana endocarditis in three homeless men. N Engl J Med (1995) 4.99

Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. GUSTO-I (Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries) Trial Investigators. Circulation (2000) 4.46

Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet (1999) 4.36

AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation (1996) 3.00

Perivalvular abscesses associated with endocarditis; clinical features and prognostic factors of overall survival in a series of 233 cases. Perivalvular Abscesses French Multicentre Study. Eur Heart J (1999) 2.90

Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin Infect Dis (2000) 2.87

Linear chromosome of Borrelia burgdorferi. Res Microbiol (1989) 2.68

Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation (1995) 2.53

Two genomic species in Borrelia burgdorferi. Res Microbiol (1990) 2.53

Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet (2001) 2.23

Two distinct types of trimethoprim-resistant dihydrofolate reductase specified by R-plasmids of different compatibility groups. J Biol Chem (1977) 2.13

Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med (1999) 2.10

Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA (1999) 2.08

Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker. Eur Heart J (2002) 2.06

One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. GUSTO-I Investigators. Circulation (1996) 2.03

Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. Circulation (1996) 1.87

Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation (1999) 1.83

Haemophilus endocarditis: report of 42 cases in adults and review. Haemophilus Endocarditis Study Group. Clin Infect Dis (1997) 1.75

Nosocomial acquisition of multiresistant Acinetobacter baumannii: risk factors and prognosis. Clin Infect Dis (1995) 1.74

Infective endocarditis in Europe: lessons from the Euro heart survey. Heart (2005) 1.70

Protease II from Escherichia coli. Purification and characterization. J Biol Chem (1975) 1.67

Late results of percutaneous mitral commissurotomy in a series of 1024 patients. Analysis of late clinical deterioration: frequency, anatomic findings, and predictive factors. Circulation (1999) 1.61

Recommendations on the management of the asymptomatic patient with valvular heart disease. Eur Heart J (2002) 1.59

Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries. Eur Heart J (1999) 1.57

Percutaneous mitral commissurotomy in the elderly. Eur Heart J (1995) 1.53

Regulation of expression and nucleotide sequence of the Escherichia coli dapD gene. J Biol Chem (1984) 1.50

Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Circulation (2000) 1.48

Combined antiplatelet therapy with ticlopidine and aspirin. A simplified approach to intracoronary stent management. Eur Heart J (1996) 1.47

Influence of late reopening of the infarct-related artery on left ventricular remodelling after myocardial infarction. IRIS Study Group. Eur Heart J (1997) 1.45

Immediate and mid-term results of repeat percutaneous mitral commissurotomy for restenosis following earlier percutaneous mitral commissurotomy. Eur Heart J (2000) 1.45

[Risk factors management in 5708 ambulatory patients suffering from peripheral vascular disease followed in urban practices]. Arch Mal Coeur Vaiss (2005) 1.45

Nucleotide sequence and expression of the Escherichia coli dapB gene. J Biol Chem (1984) 1.44

Molecular cloning, characterization, and chromosomal localization of dapF, the Escherichia coli gene for diaminopimelate epimerase. J Bacteriol (1987) 1.43

Cloning, characterization, and expression of the dapE gene of Escherichia coli. J Bacteriol (1992) 1.42

Recurrent ischemia after thrombolysis: importance of associated clinical findings. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-plasminogen activator] for Occluded Coronary Arteries. J Am Coll Cardiol (1998) 1.42

Purification and characterization of RNA polymerase from the cyanobacterium Anabaena 7120. J Biol Chem (1987) 1.42

Chromosomal location and nucleotide sequence of the Escherichia coli dapA gene. J Bacteriol (1986) 1.41

Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study. Eur Heart J (2000) 1.40

Open mitral commissurotomy or percutaneous mitral commissurotomy? J Heart Valve Dis (1994) 1.40

[Patent foramen ovale percutaneous closure: indications, techniques and results]. Ann Cardiol Angeiol (Paris) (2007) 1.39

Transfer of the posterior tricuspid leaflet and chordae for mitral valve repair. J Thorac Cardiovasc Surg (1995) 1.39

Accumulation of small heat shock proteins, including mitochondrial HSP22, induced by oxidative stress and adaptive response in tomato cells. Plant J (1998) 1.36

Immediate results of percutaneous mitral commissurotomy. A predictive model on a series of 1514 patients. Circulation (1996) 1.35

Infected infrarenal aortic aneurysms: when is in situ reconstruction safe? J Vasc Surg (1993) 1.34

Results of percutaneous mitral commissurotomy in 200 patients. Am J Cardiol (1989) 1.34

Guidelines for prevention of thromboembolic events in valvular heart disease. Ad Hoc Committee of the Working Group on Valvular Heart Disease, European Society of Cardiology. J Heart Valve Dis (1993) 1.29

Incorporation of LL-diaminopimelic acid into peptidoglycan of Escherichia coli mutants lacking diaminopimelate epimerase encoded by dapF. J Bacteriol (1988) 1.26

Guidelines for prevention of thromboembolic events in valvular heart disease. Study Group of the Working Group on Valvular Heart Disease of the European Society of Cardiology. Eur Heart J (1995) 1.21

Small abnormal echos after mitral valve replacement with bileaflet mechanical prostheses: predisposing factors and effect on thromboembolism. J Heart Valve Dis (1993) 1.19

Mortality within 24 hours of thrombolysis for myocardial infarction. The importance of early reperfusion. The GUSTO Investigators, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Circulation (1994) 1.19

Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA. Eur Heart J (2003) 1.16

Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. J Am Coll Cardiol (1997) 1.15

Bacterial contamination of hospital physicians' stethoscopes. Infect Control Hosp Epidemiol (1999) 1.14

Double mitral homograft for recurrent bacterial endocarditis of the mitral and tricuspid valves. J Heart Valve Dis (1994) 1.13

Fate of circulating immune complexes in infective endocarditis. Am J Med (1979) 1.12

Scattering of the rRNA genes on the physical map of the circular chromosome of Leptospira interrogans serovar icterohaemorrhagiae. J Bacteriol (1992) 1.10

Antimicrobial resistance among urinary tract infection (UTI) isolates in Europe: results from the SENTRY Antimicrobial Surveillance Program 1997. Antonie Van Leeuwenhoek (2000) 1.09

Construction of hybrid plasmids containing the lysA gene of Escherichia coli: studies of expression in Escherichia coli and Saccharomyces cerevisiae. Mol Gen Genet (1981) 1.06

Contemporary criteria for the selection of patients for percutaneous balloon mitral valvuloplasty. Heart (2002) 1.01

Antegrade transseptal coronary angiography: an alternative technique in severe vascular disease. Cathet Cardiovasc Diagn (1998) 1.01

Overproduction and characterization of the iclR gene product of Escherichia coli K-12 and comparison with that of Salmonella typhimurium LT2. Gene (1991) 1.00

Cardiac manifestations of rheumatoid arthritis: a case-control transesophageal echocardiography study in 30 patients. Arthritis Rheum (2001) 1.00

[Sensitivity of Pseudomonas aeruginosa and Klebsiella spp. to ceftazidime. Current status in France]. Presse Med (1988) 1.00

Frequency of occurrence and antimicrobial susceptibility of bacterial pathogens associated with skin and soft tissue infections during 1997 from an International Surveillance Programme. SENTRY Participants Group. Eur J Clin Microbiol Infect Dis (1999) 0.99

Specifics of technique in percutaneous mitral commissurotomy in a case of dextrocardia and situs inversus with mitral stenosis. Cathet Cardiovasc Diagn (1996) 0.98

Antimicrobial resistance: harmonisation of national antimicrobial resistance monitoring and surveillance programmes in animals and in animal-derived food. Rev Sci Tech (2001) 0.97

[Isolation and purification of Escherichia coli K12 genes involved in the biosynthesis of lysine]. C R Seances Acad Sci III (1981) 0.96

Subunit structure of aspartokinase 3 of Escherichia coli K12. Eur J Biochem (1973) 0.96

Integration of molecular characterization of microorganisms in a global antimicrobial resistance surveillance program. Clin Infect Dis (2001) 0.96

Nucleotide sequence of the metA gene encoding homoserine trans-succinylase in Escherichia coli. Nucleic Acids Res (1989) 0.95

Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. Circulation (1999) 0.95

Antimicrobial resistance among community-acquired pneumonia isolates in Europe: first results from the SENTRY antimicrobial surveillance program 1997. SENTRY Participants Group. Int J Infect Dis (1999) 0.95

The relA locus and the regulation of lysine biosynthesis in Escherichia coli. Mol Gen Genet (1980) 0.95

Frequency and prognostic value of cardiac troponin I elevation after coronary stenting. Am J Cardiol (1999) 0.95

Minimal myocardial damage during coronary intervention is associated with impaired outcome. Eur Heart J (1999) 0.94

Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol (2000) 0.94

Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. Circulation (2001) 0.93

Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial. Circulation (2000) 0.93

Native cardiac disease predisposing to infective endocarditis. Eur Heart J (1995) 0.93

Simultaneous determination of 5-hydroxymethylfurfural and patulin in apple juice by reversed-phase liquid chromatography. J Chromatogr A (1999) 0.92

A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur Heart J (2001) 0.92

Surgical correction of chronic postembolic obstructions of the pulmonary arteries. J Thorac Cardiovasc Surg (1978) 0.92